BioSpace News Archive

Biotech Bay

Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer

Innovent Biologics, Inc. delivered two oral presentations of its first-in-class anti-CLDN18.2/CD3 bispecific antibody for the treatment of advanced pancreatic cancer and gastric or gastroesophageal tumors at the 2024 American Society of Clinical Oncology Annual Meeting from clinical data of a Phase I study.

June 2, 2024
·
9 min read
Pharm Country

Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma

GSK plc announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating belantamab mafodotin, in combination with pomalidomide plus dexamethasone, versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma.

June 2, 2024
·
10 min read